Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

Khapzory
(levoleucovorin)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication requested:
☐ Khapzory 175mg powder for injection ☐ Khapzory 300mg powder for injection ICD10:

Dose: Frequency of therapy: Duration of therapy:

What is your patient's current weight? _____ What is your patient's current height?_____

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

Where will this medication be obtained?
☐ Accredo Specialty Pharmacy *(Cigna's nationally preferred specialty pharmacy)*
☐ Physician's office stock
☐ Home Health / Home Infusion vendor (name):
CPT Code(s):_____
☐ Ambulatory Infusion Center
☐ Hospital - In patient
☐ Hospital - Out patient
☐ Other *(please specify)*:

Facility and/or doctor dispensing and administering medication:
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

Is the patient a candidate for home infusion? Yes ☐ No ☐
Does the physician have an in-office infusion site? Yes ☐ No ☐

Diagnosis related to use:
☐ acute lymphocytic leukemia (ALL) including pediatric lymphoblastic leukemia
☐ Adult T-cell leukemia/lymphoma (ATLL)
☐ AIDS-related B-cell lymphoma
☐ anal carcinoma
☐ bladder cancer
☐ Burkitt lymphoma
☐ central nervous system cancers including primary CNS lymphoma, brain metastases, leptomeningeal metastates
☐ cervical cancer
☐ chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
☐ colorectal cancer (CRC)
☐ diffuse large B-cell lymphoma (DLBCL)
☐ esophageal and esophagogastric junction cancers
☐ extranodal NK/T-cell lymphoma (nasal type)
☐ follicular lymphoma (FL)
☐ gastric cancer
☐ hepatocellular carcinoma (HCC)
☐ high-grade B-cell lymphoma
☐ mantle cell lymphoma (MCL)
☐ neuroendocrine and adrenal tumors
☐ occult primary

☐ ovarian cancer/fallopian tube cancer/primary peritoneal cancer - mucinous carcinoma
☐ pancreatic adenocarcinoma
☐ peripheral T-cell lymphoma
☐ rhabdomyosarcoma
☐ small bowel adenocarcinoma
☐ none of the above

(if none of the above) Which of the following best describes how the patient is or will be using Khapzory?
☐ to diminish the toxicity and counteract the effects of impaired methotrexate elimination
☐ to diminish toxicity and counteract the effects of inadvertant overdosage of folic acid antagonists
☐ as rescue therapy after high-dose methotrexate therapy in osteosarcoma patient
☐ none of the above
(if none of the above) What is the diagnosis related to use?_____

Clinical Information:

(if CRC) Does your patient have metastatic disease? ☐ Yes ☐ No
(if CRC) Is/Will Khapzory be(ing) used in combination with fluorouracil (Adrucil, 5-FU)? ☐ Yes ☐ No
(if CRC) Is Khapzory being given as part of adjuvant therapy? ☐ Yes ☐ No
(if NOT CRC, if NOT none of the above) Is/Will Khapzory be(ing) used in combination with high-dose methotrexate (MTX)? ☐ Yes ☐ No
Is your patient able to obtain leucovorin injection? ☐ Yes ☐ No

Additional Pertinent Information: *(including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):*

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature:_____ **Date:**_____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

V072220

Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005